These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19270646)

  • 1. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.
    Brody JR; Costantino CL; Potoczek M; Cozzitorto J; McCue P; Yeo CJ; Hruban RH; Witkiewicz AK
    Mod Pathol; 2009 May; 22(5):651-9. PubMed ID: 19270646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
    Iacobuzio-Donahue CA; Fu B; Yachida S; Luo M; Abe H; Henderson CM; Vilardell F; Wang Z; Keller JW; Banerjee P; Herman JM; Cameron JL; Yeo CJ; Halushka MK; Eshleman JR; Raben M; Klein AP; Hruban RH; Hidalgo M; Laheru D
    J Clin Oncol; 2009 Apr; 27(11):1806-13. PubMed ID: 19273710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
    Stelow EB; Shaco-Levy R; Bao F; Garcia J; Klimstra DS
    Am J Surg Pathol; 2010 Apr; 34(4):510-8. PubMed ID: 20182344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
    Furukawa T; Fujisaki R; Yoshida Y; Kanai N; Sunamura M; Abe T; Takeda K; Matsuno S; Horii A
    Mod Pathol; 2005 Aug; 18(8):1034-42. PubMed ID: 15832194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
    Lenkiewicz E; Malasi S; Hogenson TL; Flores LF; Barham W; Phillips WJ; Roesler AS; Chambers KR; Rajbhandari N; Hayashi A; Antal CE; Downes M; Grandgenett PM; Hollingsworth MA; Cridebring D; Xiong Y; Lee JH; Ye Z; Yan H; Hernandez MC; Leiting JL; Evans RM; Ordog T; Truty MJ; Borad MJ; Reya T; Von Hoff DD; Fernandez-Zapico ME; Barrett MT
    Cancer Res; 2020 Oct; 80(20):4324-4334. PubMed ID: 32928922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic alterations of familial pancreatic cancers.
    Brune K; Hong SM; Li A; Yachida S; Abe T; Griffith M; Yang D; Omura N; Eshleman J; Canto M; Schulick R; Klein AP; Hruban RH; Iacobuzio-Donohue C; Goggins M
    Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3536-42. PubMed ID: 19064568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
    Shi C; Hong SM; Lim P; Kamiyama H; Khan M; Anders RA; Goggins M; Hruban RH; Eshleman JR
    Mol Cancer Res; 2009 Feb; 7(2):230-6. PubMed ID: 19208745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation.
    Yang D; Sun X; Moniruzzaman R; Wang H; Citu C; Zhao Z; Wistuba II; Wang H; Maitra A; Chen Y
    Cell Rep Med; 2024 Sep; 5(9):101711. PubMed ID: 39232498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
    Shu C; Cheng H; Wang A; Mansukhani MM; Powell CA; Halmos B; Borczuk AC
    Mod Pathol; 2013 Feb; 26(2):239-46. PubMed ID: 22996376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
    Moore PS; Sipos B; Orlandini S; Sorio C; Real FX; Lemoine NR; Gress T; Bassi C; Klöppel G; Kalthoff H; Ungefroren H; Löhr M; Scarpa A
    Virchows Arch; 2001 Dec; 439(6):798-802. PubMed ID: 11787853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
    de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Will molecular diagnostics become established in pancreatic pathology?].
    Sipos B; Sperveslage J
    Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells.
    Bera A; Zhao S; Cao L; Chiao PJ; Freeman JW
    PLoS One; 2013; 8(12):e82282. PubMed ID: 24340014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
    Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
    Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.